首页BXPHF • OTCMKTS
add
Botanix Pharmaceuticals Ltd
市场资讯
财务信息
损益表
收入
净收入
| (AUD) | 2024年12月info | 年同比变化 |
|---|---|---|
收入 | 18.88万 | -0.09% |
经营支出 | 1557.02万 | 532.16% |
净收入 | -1544.41万 | -464.98% |
净利润率 | -8180.16 | -465.47% |
每股收益 | — | — |
息税折旧摊销前利润 | -1542.67万 | -459.15% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (AUD) | 2024年12月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 4843.69万 | 164.49% |
总资产 | 9944.78万 | 108.57% |
负债总额 | 695.98万 | 203.76% |
权益总额 | 9248.80万 | — |
发行在外的股份 | 18.18亿 | — |
市净率 | 4.60 | — |
资产回报率 | -40.19% | — |
资本回报率 | -42.81% | — |
现金流
现金净变动
| (AUD) | 2024年12月info | 年同比变化 |
|---|---|---|
净收入 | -1544.41万 | -464.98% |
来自运营的现金 | -1528.08万 | -712.75% |
投资现金 | -42.70万 | 94.22% |
融资现金 | 20.02万 | -98.50% |
现金净变动 | -1543.56万 | -482.88% |
自由现金流 | -457.30万 | 45.34% |
简介
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs. Wikipedia
成立时间
1984
员工数量
11
